Nordson said it entered into an Agreement and Plan of Merger with Atrion Corporation on May 28, 2024. Under the agreement, Merger Sub will merge into Atrion, and Atrion will survive as a wholly owned subsidiary of Nordson.

1. 01

   Nordson said it entered into an Agreement and Plan of Merger with Atrion Corporation on May 28, 2024. Under the agreement, Merger Sub will merge into Atrion, and Atrion will survive as a wholly owned subsidiary of Nordson.

2. 02

   Nordson said it is offering $460.00 per share in cash for Atrion, which values the total transaction at an enterprise value of about $800 million. The company also said the price equals 15X of Atrion's estimated full-year 2024 EBITDA, including synergies.

3. 03

   Nordson said it expects the transaction to close before the end of its fiscal 2024 year, subject to regulatory and stockholder approvals. The company said it will fund the deal with a combination of cash on hand and newly issued debt.

4. 04

   Nordson said Atrion is a medical device manufacturer based in Allen, Texas, with annual revenue of about $169 million in 2023. The company said Atrion consists of three businesses: Halkey Roberts, Atrion Medical and Quest Medical.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.